Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.78 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3935155 | 0.89 | GPR119 (0.76) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL3931381 | 0.88 | GPR119 (0.75) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL3929833 | 0.86 | GPR119 (0.60) | GPR119PDE4B | |
| SCHEMBL4493791 | 0.86 | GPR119 (0.71) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL3941387 | 0.78 | GPR119 (0.61) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL3938388 | 0.78 | GPR119 (0.78) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL3938345 | 0.76 | GPR119 (0.76) | GPR119 | |
| SCHEMBL5454387 | 0.76 | GPR119 (0.57) | GPR119KDM1APDE4BPDE4DPDE4A | |
| SCHEMBL2116540 | 0.75 | GPR119 (0.65) | GPR119PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL3934713 | 0.73 | GPR119 (0.55) | GPR119KDM1APDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222261-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2009-12-24 | — | — | US | disclosed |
| EP-2043744-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008008895-A1 | GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008887-A2 | GPR119 AGONISTS FOR TREATING METABOLIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318477-A1 | CHEMICAL COMPOUNDS | GPR119, GOT2, SLC5A2 | GPR119 1/4885KDM1A 4302/4885PDE4B 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.